See the DrugPatentWatch profile for ruxolitinib

Based on the available information, it cannot be definitively confirmed if Apotex has resubmitted Ruxolitinib for FDA (Food and Drug Administration) consideration. However, it is known that Ruxolitinib is a drug currently under review by health regulatory agencies.

Ruxolitinib is a medication used to treat certain types of blood cancer and is marketed under the brand name Jakafi by Incyte Corporation [1]. Apotex, a Canadian-based pharmaceutical company, may have submitted a generic version of Ruxolitinib for approval [2].

According to the FDA's website, Ruxolitinib was approved for marketing in the United States in November 2011 [3]. However, the FDA website does not provide information on the status of generic drug submissions.

Health Canada's website lists Ruxolitinib as a drug with generic submissions under review [2]. However, the specific companies and the status of these submissions are not provided.

In conclusion, while it is known that Ruxolitinib is under review by health regulatory agencies, the available information does not provide a definitive answer as to whether Apotex has resubmitted Ruxolitinib for FDA consideration.

Sources:

* [1] DrugPatentWatch. (n.d.). Ruxolitinib. Retrieved from <https://www.drugpatentwatch.com/p/tradename/RUXOLITINIB>
* [2] Government of Canada. (n.d.). Generic Submissions Under Review. Retrieved from <https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/generic-submissions-under-review.html>
* [3] U.S. Food and Drug Administration. (2011, November 16). FDA approves new drug to treat myelofibrosis, a type of blood cancer. Retrieved from <https://www.fda.gov/media/121326/download>